Nurix Therapeutics Inc At ASH Annual Meeting Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Derek Archila - Wells Fargo - Analyst : Derek Archila, Wells Fargo. I just was wondering if you could comment on the duration of exposure and kind of the response kinetics that we're seeing for 5948. How does that compare to what we saw with Beijing? And I guess the expectation that some of these PRs might convert to CRs. Nirav Shah^ Yeah. I mean so Beijing had longer median duration of follow up. If you saw that presentation, I think there are about 10 months and here our duration of treatment is shorter and, and we're clearly seeing the deepening of response. We saw it in the CLL group, we saw it in the Waldenstroms and that's actually consistent with other BTK targeting drugs. So there are patients that have achieved normal counts, but not all investigators have done a marrow to look and see if they've actually cleared the marrow. So it is very possible that some of these PERs convert to CRs, I'd also like to take a step back. And if you heard me during the presentation, the focus on CR is misguided, right, like that's not necessarily the end point that matters for all of these patients, right? Getting into ACR and CLL doesn't mean you're cured, right? It just means the depth of remission but controlled disease, taking a pill and feeling well is also okay, especially in the setting that this is being used as like 1/5 line treatment, right? Median of four prior lines. So it's just each lymphoma is very different and there are other lymphomas where CR is what the whole story is about. But PRs and good quality of life and an oral agent that's tolerable with good duration of response, which again, we need more follow up. I'll keep saying that I think is actually an important endpoint more than aiming for this CR.